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 43 
ABSTRACT 44 
 45 
 46 
High rates of APOBEC-signature mutations are found in many tumors, but factors affecting this 47 
mutation pattern are not well understood. Here, we explored the contribution of two common 48 
germline variants in the APOBEC3 region. A single nucleotide polymorphism, rs1014971, was 49 
associated with bladder cancer risk, increased APOBEC3B (A3B) expression, and enrichment 50 
with APOBEC-signature mutations in bladder tumors. In contrast, a 30 Kb deletion that 51 
eliminates A3B and creates A3AB chimera, was not important in bladder cancer, while being 52 
associated with breast cancer risk and enrichment with APOBEC-signature mutations in breast 53 
tumors. In vitro, A3B was predominantly induced by treatment with a DNA-damaging drug in 54 
bladder cancer cell lines and A3A was induced as part of antiviral interferon-stimulated response 55 
in breast cancer cell lines. These findings suggest a tissue-specific role of environmental 56 
oncogenic triggers, particularly in individuals with germline APOBEC3 risk variants.  57 
 58 
 59 
 60 
 61 
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TEXT 68 
Somatic mutations of a specific type (C to T or G substitutions in the TCA or TCT motifs) have 69 
been described in many tumors as APOBEC-signature mutations1-5. These mutations are 70 
generated by cytidine deaminase activity of proteins belonging to the apolipoprotein B mRNA-71 
editing enzyme, catalytic polypeptide-like (APOBEC) family6,7. APOBEC-signature 72 
mutagenesis has been linked with activity of two members of the APOBEC3 subfamily - 73 
APOBEC3B (A3B) and APOBEC3A (A3A)3,8,9. All APOBEC3 proteins (A3A, A3B, A3C, 74 
A3D, A3F, A3G, and A3H) are encoded by genes located within a 200 Kb APOBEC3 genomic 75 
cluster on chromosome 22q13.1.  76 
 77 
Two common germline variants in this region have been associated with cancer risk. The first 78 
variant is a single nucleotide polymorphism (SNP), rs1014971, which is located upstream of the 79 
APOBEC3 cluster10. This SNP has been associated with risk for bladder cancer in a genome-80 
wide association study (GWAS) in individuals of European ancestry10, and replicated in a 81 
Japanese study11. The second variant is a 30 Kb deletion, which fuses the coding region of A3A 82 
with the 3’ untranslated region (3’UTR) of A3B, resulting in the loss of A3B and the gain of 83 
chimeric transcript A3AB that encodes A3A12. Both A3A and A3AB transcripts encode A3A 84 
enzyme, but the presence of the 3’UTR from A3B increases the stability of the A3AB transcript 85 
and A3A levels in vitro13. The deletion has been associated with increased risk for breast and 86 
ovarian cancers14-16, as well as enrichment with APOBEC-signature mutations in breast 87 
tumors8,17.  88 
 89 
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Since APOBEC-signature mutations have been described in both bladder and breast tumors2,3, 90 
and associations with germline variants within the APOBEC3 region have been reported for 91 
these cancers, we explored whether germline variants in this region are associated with 92 
APOBEC-mutagenesis. We also tested some environmental exposures that may induce A3A and 93 
A3B expression and contribute to APOBEC-signature mutation pattern. 94 
 95 
RESULTS 96 
Fine-mapping and association analysis of the APOBEC3 region  97 
SNP rs1014971 is the original GWAS signal within the 22q13.1 region detected for bladder 98 
cancer risk at a genome-wide significance level (p=8.4E-12)10. This SNP is located in an 99 
intergenic region, 66 Kb upstream of CBX6 and 20 Kb upstream of A3A, which is the first gene 100 
in the APOBEC3 gene cluster. We performed fine-mapping analysis of the region based on 3,125 101 
imputed and 137 genotyped SNPs in the combined bladder cancer NCI-GWAS set of individuals 102 
of European ancestry (5,832 cases/10,721 controls)10,18. The strongest associations were detected 103 
for three correlated SNPs (all in r2 = 1.0) - the original GWAS SNP, rs1014971, and two 104 
additional SNPs, rs1004748 and rs17000526 (Figure 1, Table S1). There was no evidence for a 105 
significant independent signal after adjusting for rs1014971 (Table S1). Based on data generated 106 
by the Breast Cancer Association Consortium (BCAC)19, these three SNPs were also associated 107 
with breast cancer risk in the same direction as in bladder cancer, albeit weaker, and only in 108 
women with ER+ breast tumors (in Europeans, OR = 1.03, P = 0.0072 for rs1014971-T allele, 109 
Figure S1). 110 
 111 
 5 
 
The A3AB deletion has been significantly associated with increased breast cancer risk14-16; thus 112 
we tested its association with bladder cancer risk. The deletion status was determined directly, by 113 
a copy number variation (CNV) assay or indirectly, by TaqMan genotyping of SNP rs12628403 114 
(Figure S2, Table S2), which has been strongly associated with breast cancer risk in a Chinese 115 
population16. We confirmed rs12628403 to be the only available proxy for the CNV with D’ = 116 
1.0, r2 = 1.0 in Europeans and Japanese, D’ = 1.0, r2 = 0.95 in Chinese, but not in Africans where 117 
the CNV has 4.2% frequency while rs12628403 is monomorphic (in 1000 Genomes Project 118 
populations, Figure S3). Both the CNV and rs12628403 cannot be imputed based on existing 119 
1000 Genomes Project data (Figure S4) and thus require genotyping.  120 
 121 
The deletion was more common in controls than in cases both in individuals of European and 122 
Japanese ancestry (Table 1); the meta-analysis results showed a significantly reduced bladder 123 
cancer risk in carriers of the deletion (OR = 0.85, 95% CI 0.74-0.97, P = 0.013, Table 1). 124 
However, association for the deletion disappeared after adjustment for the effect of rs1014971 125 
(Table S3); haplotype analysis of the two variants also showed that association was driven by 126 
rs1014971 (Table 2). Thus, the effect of the deletion on bladder cancer risk seems to be 127 
subsumed by rs1014971.  128 
 129 
SNP rs17000526 is associated with A3B expression in bladder and breast tumors in TCGA 130 
We analyzed data generated by The Cancer Genome Atlas (TCGA) focusing on a 400 Kb region 131 
that included the APOBEC3 gene cluster and flanking genes. We evaluated expression of each 132 
gene isoform within this region in relation to SNP rs17000526 (a TCGA-genotyped proxy for 133 
rs1014971, r2 = 1.0). Only expression of the major A3B isoform (uc003awo.1, further referred to 134 
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as A3B) was significantly associated with rs17000526 in bladder and breast tumors, with higher 135 
expression observed in carriers of the risk allele A (Table S4 and S5 for exploratory analysis 136 
adjusting only for age, sex, and race). In an expanded multivariate linear regression analysis of 137 
A3B expression we evaluated effects of SNP rs17000526, age, sex, race, DNA methylation of a 138 
CpG site found to be significantly associated with A3B expression (Table S6), and somatic copy 139 
number variation (CNV). This analysis showed significant association of SNP rs17000526 with 140 
A3B expression, with per-allele beta-coefficients = 0.25, P = 5.37E-04 for bladder tumors 141 
(Figure 2A and B) and 0.19, P = 5.99E-03 for breast tumors (Figure 2C and D).  142 
 143 
APOBEC mutagenesis is significantly predicted by SNP rs17000526 and A3B and A3A 144 
expression in bladder tumors but by A3AB deletion and A3A expression in breast tumors 145 
Next, we analyzed APOBEC mutagenesis using two variables - total counts of APOBEC-146 
signature mutations and APOBEC mutagenesis pattern using public datasets available through 147 
Firehose portal (Materials and Methods and Supplementary Source file 1). APOBEC 148 
mutagenesis pattern is a more stringent definition that represents statistically significant 149 
enrichment with APOBEC-signature mutations over random mutagenesis3,20. Most of TCGA 150 
bladder tumors with APOBEC-signature mutations (347/395) but only a quarter of breast tumors 151 
(224/977) show APOBEC mutagenesis pattern. Although analysis of both metrics generated very 152 
similar results, we provide them side by side for comparison. In bladder tumors SNP rs17000526 153 
was strongly associated with APOBEC-signature mutations (beta-coefficient = 0.18, P = 1.92E-154 
05, Figure 2E and F) and APOBEC mutagenesis pattern (beta-coefficient = 0.23, P = 3.17E-05, 155 
Figure 2I and J). Among the 14 known bladder cancer GWAS signals, the association with 156 
APOBEC-signature mutations was specific to rs17000526 (Table S7). However, rs17000526 157 
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was not associated with APOBEC mutagenesis in breast tumors (Figure 2G, H, K and L). In 158 
bladder tumors, rs17000526 and expression of major isoforms of A3B and A3A were significant 159 
independent predictors of both metrics of APOBEC mutagenesis – with beta-coefficients of 0.15 160 
and 0.20 for the SNP, 0.14 and 0.17 for A3B expression and 0.05 and 0.10 for A3A (Figure 2M 161 
and N). In breast tumors, Asian ancestry, expression of major A3A isoform and A3AB deletion 162 
isoform (corresponds to A3AB germline deletion) were significant independent predictors of both 163 
metrics of APOBEC mutagenesis with beta-coefficients of 0.29 and 0.35 for Asian ancestry, 0.17 164 
and 0.15 for A3A expression and 0.13 and 0.11 for A3AB deletion (Figure 2O and P). Expression 165 
levels of A3C, A3F and A3H isoforms were less predictive and all other APOBEC3 isoforms 166 
were not predictive of APOBEC mutagenesis in bladder and breast tumors (Tables S8, S9).  167 
 168 
SNP rs1014971 shows allele-specific protein binding in bladder cancer cell lines 169 
The three linked SNPs associated with bladder and breast cancer risk, rs1014971, rs17000526, 170 
and rs1004748, are located within a 2 Kb genomic region 20 Kb upstream of A3A. Previously, 171 
this region has been reported as a putative long-distance enhancer that interacts with the A3B 172 
promoter in lymphoblastoid and bone marrow (CD34+) cells21. Since variants within the A3B 173 
promoter were not associated with breast cancer22, mRNA expression and cancer risk could be 174 
affected by variation within the long-distance enhancer region. In silico functional annotation of 175 
the 2 Kb region showed an enrichment of functional marks characteristic of an enhancer activity 176 
around rs17000526 (Figure 3A).  177 
 178 
However, electrophoretic mobility shift assays (EMSA) did not show allele-specific binding 179 
patterns for rs1004748 and rs17000526 with nuclear protein extracts from two bladder cancer 180 
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cell lines (HT-1376 and RT-4) and breast cancer cell line MCF-7 (Figure 3B). In contrast, in 181 
bladder cancer cell lines the binding was exclusive for the rs1014971-T risk allele, while in the 182 
breast cancer cell lines some binding was also observed for the rs1014971-C non-risk allele 183 
(Figure 3B). This binding pattern for rs1014971 was validated in three additional cell lines 184 
(Figure S5). This is in line with the stronger association of this SNP with A3B expression in 185 
bladder compared to breast tumors (beta-coefficient = 0.25 vs. 0.19, respectively, Figure 2A and 186 
C) and stronger estimated effect of this SNP for bladder (OR = 1.13)18 compared to ER+ breast 187 
cancer risk (OR = 1.03, Figure S1).  188 
 189 
APOBEC3s can be induced by environmental exposures in tissue-specific manner 190 
APOBEC3s are ubiquitously expressed in many human tissues and cell types23 (Figure S6), but 191 
their endogenous baseline expression levels are likely to be non-genotoxic, as has been 192 
demonstrated for A3A24. APOBEC3s are mutagenic when overexpressed in vitro24-26, but it is 193 
unclear what induces their endogenous expression under physiological conditions. Some 194 
APOBECs can be induced as a part of interferon-driven innate immune response to viral 195 
pathogens, e.g. induction of A3G that restricts human immunodeficiency virus (HIV)27. 196 
Induction of A3A and A3B by interferons has also been demonstrated28,29.  197 
 198 
To test if A3A, A3B and A3G (used as a control) can be induced as a part of interferon response, 199 
we infected three bladder (HT-1376, HTB-9 and RT-4) and three breast cancer cell lines (MCF-200 
7, MDA-MB-231 and  T-47D) with Sendai virus (SeV), which is a model non-lytic RNA-virus 201 
that induces robust interferon response in diverse human cells30. These cell lines were chosen 202 
because they represent some of the major clinical subtypes of bladder and breast tumors 203 
 9 
 
(Materials and Methods). As expected for response to an RNA virus31,32, we observed strong 204 
induction of many known interferon-stimulated genes, including A3G (Table S10). There was 205 
striking induction of A3A (by 32, 51 and 12,000 fold) in the three breast cancer cell lines, in 206 
contrast to a more moderate induction (4, 5 and 167 fold) in the three bladder cancer cell lines 207 
(Figure 4, Figures S7, S8). However, A3B was induced only by 0.84 - 1.75 fold in SeV- infected 208 
bladder cancer cells and by 0.15 - 4.89 fold in breast cancer cells, which could be due to 209 
relatively high A3B expression already at baseline (Figure 4, Figure S7, S8).  210 
 211 
APOBEC3s introduce mutations by editing single-stranded DNA (ssDNA), which is abundant in 212 
conditions associated with DNA damage, repair and replication33, but it is unknown if DNA 213 
damage can induce expression of APOBEC3s. To test this, we treated cells with bleomycin, a 214 
DNA-damaging drug known to induce DNA breaks34; expression analysis confirmed that 215 
interferon response was not induced by this treatment (Table S10). Both A3A and A3B were 216 
induced in all cell lines but the effect was more robust for A3B, especially in bladder cancer cell 217 
lines (Figure 4, Figure S7, S8). In all cell lines A3A expression was much lower than A3B at 218 
baseline (Figure 4). However, viral infection in breast cancer cells strongly induced A3A, up and 219 
above A3B expression levels. A3G was induced in some cell lines by both treatments (Figure 4, 220 
Figure S7, S8), but A3G is a cytoplasmic enzyme that does not edit TC motifs3 and thus is not 221 
expected to generate APOBEC-signature mutations.  222 
 223 
APOBEC mutagenesis is the best predictor of survival of bladder cancer patients 224 
Multivariate analysis showed that survival of TCGA bladder cancer patients was most 225 
significantly predicted by tumor stage and APOBEC mutagenesis, while treatment (Yes/No) was 226 
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not a significant predictor (Table S11). Survival was improved by more than 2-fold (P = 2.41E-227 
04) in patients with mutation counts above vs. below median levels (73 for APOBEC-signature 228 
mutations and 49 for mutagenesis pattern mutations) (Figure 5A, 5B). Survival in relation to 229 
APOBEC mutagenesis is also presented in Firehose (Materials and Methods). The effect of the 230 
SNP was in the same direction, with individuals homozygous for the bladder cancer risk allele 231 
having longer survival (p=0.067, Figure 5, Table S11). Association of rs17000526 with survival 232 
was fully explained by APOBEC mutagenesis, although adjustment for rs17000526 had only 233 
moderate effect (Table S11), suggesting that many factors, including rs17000526 contribute to 234 
APOBEC mutagenesis.  235 
 236 
We also evaluated effects of all APOBEC3 isoforms on survival. The effect of A3B expression 237 
was comparable to that of rs17000526 and similar in treated and untreated patients (beta-238 
coefficients = -0.26 and -0.27), while the effect of A3A expression was stronger in treated 239 
compared to untreated patients (beta-coefficients = -0.41 vs. 0.05, Table S11). Some isoforms of 240 
A3D and A3H significantly predicted survival but only in treated patients, in line with a recent 241 
analysis of survival in 73 bladder cancer patients treated with adjuvant platinum-based therapy35. 242 
It is unclear whether these effects are related to APOBEC mutagenesis or inflammatory 243 
microenvironment and infiltration with PD-L1 expressing mononuclear cells observed in these 244 
tumors35.     245 
 246 
For breast cancer there was a similar but non-significant trend for better survival in patients with 247 
ER+ tumors and high APOBEC-signature mutation counts; there was also association between 248 
survival and rs17000526, but only in ER- breast tumors (Figure S9). Of A3A and A3B transcripts 249 
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only expression of A3AB was significantly associated with survival, with ER+ carriers of this 250 
germline deletion having significantly worse survival (beta-coefficient = 0.64, p = 0.006, Figure 251 
S9).   252 
 253 
Increased A3B expression has been observed in breast tumors with somatic mutations in the 254 
tumor suppressor TP53 gene and this was explained by improved survival of cells with high 255 
APOBEC-signature mutation loads when TP53 is inactivated4. TP53 is the most commonly 256 
mutated gene in bladder tumors and we observed that TP53 mutations were more common in the 257 
rs17000526-AA genotype group (Table S12). The same trend was observed for mutations in 258 
PIK3CA, the 5th most commonly mutated gene in bladder tumors (Table S13), and TP53 259 
mutations in ER- breast tumors (Table S14). Adjustment for presence of TP53 mutations did not 260 
significantly affect the association between rs17000526, APOBEC-signature mutations, and 261 
survival of bladder and breast cancer patients (Table S12, Table S14).  262 
 263 
DISCUSSION  264 
Although somatic mutations emerge on the background of germline variants, some of which are 265 
associated with increased predisposition to cancer, the relationships between germline and 266 
somatic mutations are largely unknown. Mutation profiles within genomic regions harboring 267 
GWAS signals have been explored for a range of cancers, but genes with common germline risk 268 
variants are not enriched for somatic mutations36, unlike the highly penetrant familial cancer 269 
genes37. However, our study shows that common germline variants within the APOBEC3 region 270 
that affect expression of APOBEC3s, the mutation-causing enzymes, are associated both with 271 
cancer predisposition and global somatic mutation profiles.  272 
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 273 
Our results suggest that A3B is a predominant source of APOBEC-signature mutations in 274 
bladder and A3A in breast tissue. Bladder cancer risk is increased in carriers of SNP rs1014971-275 
T allele and we suggest this could be because of its association with increased expression of A3B 276 
and generation of APOBEC-signature mutations in bladder tissue. Although the functional effect 277 
of the A3AB deletion that eliminates A3B and creates the A3A-encoding A3AB transcript could 278 
be substantial, its genetic association with bladder cancer risk was subsumed by SNP rs1014971. 279 
In contrast, breast cancer risk is only moderately associated with SNP rs1014971 but strongly 280 
with the A3AB deletion, and the enrichment with APOBEC-signature mutations is strongly 281 
associated with expression of A3A and A3AB, but not A3B.  282 
 283 
We also show that expression of A3A and A3B is inducible by environmental exposures. 284 
Treatment with a DNA-damaging drug, bleomycin, induced A3B in all cell lines tested, with the 285 
effect being most robust in bladder cancer cell lines. DNA damage as a result of exposure to 286 
environmental carcinogens is specifically important for bladder cancer because of direct contact 287 
of bladder epithelium with bioactive metabolites that accumulate in urine. Exposures to 288 
occupational and environmental carcinogens strongly increase the risk for bladder cancer, and 289 
germline susceptibility variants may modify this risk38. SNP rs1014971 has already been shown 290 
to significantly modify bladder cancer risk caused by tobacco smoking, the most known 291 
environmental risk factor39, and our results suggest this could be through regulation of A3B 292 
expression by this SNP contributing to APOBEC-signature mutagenesis.  293 
 294 
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In contrast, A3A expression was uniformly induced by viral infection, with 30-12,000-fold 295 
induction in breast cancer cell lines, and 4-167 fold in bladder cancer cell lines. This range of 296 
induction suggest additional cell-type specific factors that may affect sensitivity to different 297 
environmental exposures. A3AB deletion has been associated with interferon-induced 298 
inflammatory gene expression profile in breast tumors40, supporting our conclusions that A3A 299 
(and A3AB) is part of this profile. Although in our experiments this expression was induced by 300 
an RNA virus, in vivo it might be induced by diverse stimuli that result in activation of interferon 301 
response.  302 
 303 
APOBEC3 activity has been also associated with hypermutation of some carcinogenic DNA 304 
viruses, such as human papillomavirus (HPV)28,29,41 and hepatitis B virus (HBV)28,42. APOBEC 305 
mutagenesis contributes to noncytolytic clearance of these viruses but can also result in increased 306 
viral diversity and APOBEC-signature mutagenesis in tumors. Response to DNA viruses might 307 
depend on tissue-specific repertoire of APOBECs and cellular mechanisms induced by particular 308 
infections, such as interferon-stimulated antiviral response, virally-induced DNA damage or 309 
some other specific mechanisms that need to be explored for each tissue and viral infection 310 
individually.  311 
 312 
We found that in bladder tumors SNP rs17000526, A3B and A3A expression, while in breast 313 
tumors A3AB deletion and A3A expression are significant independent predictors of APOBEC 314 
mutagenesis. We speculate that mRNA expression may capture both the germline-regulated and 315 
environmentally-inducible components that contribute (or have contributed in the past) to 316 
accumulation of APOBEC-signature mutations through the tumor history. At the same time, the 317 
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SNP may represent germline-regulated expression levels that would be relevant at the time of 318 
mutagenesis but might not be detectable by the snapshot expression analysis in excised tumors. 319 
Some other factors that might be relevant for APOBEC mutagenesis, such as environmental 320 
exposures, are impossible to quantify (both the magnitude and timing) and other factors are 321 
unknown. Based on currently available data we suggest that a combination of germline variants 322 
rs17000526 and A3AB deletion and mRNA expression of A3B and A3A in tumors may provide 323 
better prediction of APOBEC mutagenesis than each of these variables alone.  324 
 325 
Although expression of APOBEC3s (A3A, A3B and A3AB, specifically) is a likely prerequisite 326 
for APOBEC-signature mutagenesis, some factors may modify the outcome of this expression. 327 
For example, loss of FHIT protein was shown to create DNA breaks that provide substrate for 328 
APOBEC mutagenesis; TCGA lung adenocarcinoma tumors with high A3B expression and FHIT 329 
loss had higher APOBEC mutagenesis compared to tumors with high A3B expression but 330 
without FHIT loss43. 331 
 332 
Interestingly, TCGA bladder cancer patients with increased APOBEC mutagenesis (more than 333 
73 APOBEC-signature mutations or more than 49 APOBEC-mutagenesis pattern mutations) had 334 
significantly improved survival. The SNP rs17000526 showed a similar although less significant 335 
trend with each risk allele. Considering that all bladder tumors in TCGA are of the most 336 
aggressive, muscle-invasive type, this might be a clinically significant finding that requires 337 
careful follow-up. Increased mutation loads, especially in DNA repair genes, were associated 338 
with response to neoadjuvant cisplatin-based treatment of muscle-invasive bladder cancer; this 339 
was attributed to inability of cancer cells to recover after treatment-induced DNA damage44. We 340 
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observed higher TP53 and PIK3CA mutation rates in bladder tumors from patients homozygous 341 
for the rs17000526-A allele. Tumors with higher mutation burden are also more likely to be 342 
targeted by immune surveillance45 and respond to PD-1 checkpoint inhibitors46. SNP (rs1014971 343 
or its proxy rs17000526) by itself might not be informative enough for clinical use but it should 344 
be combined with other clinical, genetic and molecular markers and tested for clinical utility for 345 
management of bladder cancer. The current analysis in TCGA samples is based on whole-exome 346 
sequencing and it remains to be seen if targeted exome sequencing that is becoming common in 347 
the clinic, can provide sufficient and clinically relevant information about APOBEC 348 
mutagenesis.  349 
 350 
In conclusion, our work shows how functional germline variants and environmental exposures 351 
may affect somatic mutations in tissue-specific manner and clinical outcomes. We propose 352 
(Figure 6) that even transient exposures to relevant environmental factors might induce A3A or 353 
A3B expression above the genotoxic levels and initiate tumorigenesis in tissue-specific manner in 354 
the right cellular environment where ssDNA is available; germline APOBEC3 variants might 355 
affect both the baseline and threshold levels of A3A and A3B expression. Genomic instability and 356 
DNA breaks acquired during tumor development could provide source of ssDNA independent of 357 
external environmental exposures, further stimulate APOBEC3 expression and fuel APOBEC-358 
mediated mutagenesis and tumor evolution. On the other hand, more efficient immune 359 
surveillance due to neoantigens and synthetic lethality of tumor cells can contribute to improved 360 
survival for patients with higher APOBEC mutagenesis. Since APOBEC-signature mutagenesis 361 
has been reported in 16 of 30 tumor types analyzed by TCGA2, further work is needed to explore 362 
the relationships between germline variants and environmental factors that can affect the activity 363 
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of APOBEC enzymes, patterns of somatic mutations, cancer risk, and outcomes across cancer 364 
types. 365 
 366 
MATERIALS AND METHODS 367 
Samples 368 
Genotypes for 5,832 bladder cancer cases and 10,721 controls of European ancestry were 369 
generated by NCI-GWAS110 and NCI-GWAS218. Additional genotyping was performed for 370 
A3AB deletion in a subset of 4,285 NCI-GWAS1 samples – 1,996 samples from the Spanish 371 
Bladder Cancer Study (SBCS) and 2,289 samples from the Prostate, Lung, Colorectal, and 372 
Ovarian (PLCO) Cancer Screening Trial, USA. Additionally, 2,061 samples from controls 373 
participating in the Biobank Japan project and bladder cancer patients recruited from 11 hospitals 374 
in Japan11 were genotyped for deletion and SNP rs1014971. Samples from HapMap and the 1000 375 
Genomes Project were genotyped for deletion and SNP rs12628403. Bladder cancer NCI-GWAS 376 
is covered by the NIH Office of Human Subjects Research Protections (OHSRP) exemption 377 
(#13076). Each participating study/institution obtained informed consent from study participants 378 
and their corresponding IRBs. Specifically, active National Cancer Institute Special Studies 379 
Institutional Review Board (NCI-SSIRB) approvals cover SPBC (#OH99CN038) and PLCO 380 
(#OH97CN041). Analysis in samples from Japan was approved by IRB of the Institute of 381 
Medical Science, the University of Tokyo (#23-43-0130).  382 
Cell lines  383 
Bladder cancer cell lines (muscle-invasive HT-1376 and HTB-9 and non-muscle-invasive RT-4) 384 
and breast cancer cell lines (MCF-7 (ER+/PR+/HER2-/TP53WT), MDA-MB-231 (ER-/PR-385 
/HER2-/TP53mut) and T-47D (ER+/PR+/HER2-/TP53mut)) were purchased from the American 386 
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Type Culture Collection (Manassas, VA). Cell lines were either purchased from ATCC 387 
specifically for this project within last 4 months or authenticated by genotyping of a panel of 388 
microsatellite markers through DDC Medical service in 2016. All cell lines in the lab are 389 
regularly tested for Mycoplasma contamination using MycoAlert Mycoplasma Detection Kit 390 
(Lonza). 391 
Genotyping  392 
A3AB deletion was genotyped with a multiplexed CNV assay that included individual assays for 393 
A3B and RNAseP (Hs04504055 with FAM-fluorophore and 4403328 with VIC-fluorophore, 394 
respectively, both from Life Technologies), 2x TaqMan Expression Master Mix (Life 395 
Technologies) and 5 ng of genomic DNA. The 5-ul reactions were run in technical 396 
quadruplicates, in 384-well plates using QuantStudio 7 under standard conditions. The A3AB 397 
genotypes were scored as insertion (I/I), heterozygotes (I/D), or deletion (D/D). The assay was 398 
first tested on DNA of HapMap samples (CEU, YRI, CHB/JPT) and genotypes were found to be 399 
97.03 % concordant with those reported based on long-range PCR and gel electrophoresis12 (8 of 400 
270 samples were discordant, Table S2). Selected HapMap samples representing all genotype 401 
groups were included as positive controls and water as a negative control on each PCR plate. 402 
A3B copy number status was calculated using Ct values (PCR cycle at threshold) after 403 
normalization by Ct values of RNAseP gene which has 2 copies in the human genome. dCt values 404 
were calculated as Ct (RNAseP)-Ct (A3B). Scoring was done manually after reviewing dCt plots 405 
and blinded to sample information; 403 samples were genotyped for CNV in duplicates with 406 
99.7% concordance. Distributions of deletion genotypes in controls from Europe and Japan did 407 
not deviate from Hardy-Weinberg equilibrium (HWE) and were comparable to those expected 408 
based on data in corresponding HapMap populations (Table S15, S16). Deletion was also 409 
 18 
 
genotyped through a proxy SNP rs12628403, using a custom-designed TaqMan genotyping 410 
assay (Figure S2). 411 
Fine-mapping analyses 412 
Additional genotypes in the 22q13.1 region were inferred with IMPUTE2 software using data 413 
from the bladder cancer NCI-GWAS1 and NCI-GWAS2 datasets10,18 and the 1000 Genomes 414 
Project phase 3 reference set (October 2014 release), which contains data for 2,504 individuals 415 
from 21 populations. Imputation was performed within a 1 Mb window centered on bladder 416 
cancer GWAS SNP rs1014971. Imputation quality was assessed based on overall concordance, 417 
which indicates how well the known SNPs were imputed across samples (a threshold of 0.95 was 418 
used), the average posterior probability and the IMPUTE2-info score of individual SNPs, which 419 
indicate how well individual SNPs were imputed across a data set (a threshold of 0.9 was used). 420 
Imputation quality for SNP rs17000526 was confirmed by TaqMan genotyping of 681 samples 421 
with 99.6% concordance with imputation results. Hardy-Weinberg equilibrium and minor allele 422 
frequencies were calculated with PLINK version 1.07 (August 10, 2009) and linkage 423 
disequilibrium values (D’ and r2) were calculated with PLINK version 1.90 beta (June 10, 2014). 424 
GTOOL was used for all file conversions between pedigree and genotype file formats.  425 
Association testing was performed in the combined NCI-GWAS1 and NCI-GWAS2 dataset that 426 
included genotyped and imputed markers using PLINK version 1.07 with logistic regression 427 
models and adjusting for relevant variables: age, gender, eigenvectors 1, 5, and 6, study sites, 428 
and smoking history (ever/never smoker), as previously described10,18. To test for any additional 429 
SNPs independently associated with bladder cancer risk, models were also adjusted for bladder 430 
cancer GWAS SNP rs1014971. Association analysis for the deletion was performed in R version 431 
3.2.1 using logistic regression models. Because of the low frequency of the deletion in 432 
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individuals of European ancestry (~6%), analysis was done using a dominant genetic model 433 
(absence or presence of deletion). Models were adjusted for relevant variables as indicated. 434 
Random effects meta-analysis of Odds Ratios (ORs) between the European and the Japanese 435 
datasets was performed in STATA 13.0. All Odds Ratios are reported with 95% confidence 436 
intervals. Recombination plots were generated using R shiny app at National Cancer Institute, 437 
National Institutes of Health ( http://ccad.nci.nih.gov:3838/users/zhangt8/1kginfo/.) 438 
Recombination hot spots are informative because they disrupt linkage disequilibrium blocks. It is 439 
expected that genetic markers that represent the same association signal should be scattered 440 
within a region uninterrupted by recombination hotspots.  441 
The Cancer Genome Atlas (TCGA) data  442 
Open access data for previously described TCGA data sets47,48 and preliminary data for 443 
additional samples were downloaded  on February 2, 2015 from TCGA Data portal https://tcga-444 
data.nci.nih.gov/tcga/dataAccessMatrix.htm. Downloaded sets included demographic (age, sex, 445 
race) and clinical variables (tumor stage, treatment, survival, etc), mRNA expression (Illumina 446 
HiSeq RNASeqV2) and DNA methylation of CpG sites (Human Methylation 450). Data for 447 
somatic CNVs for TCGA samples were downloaded from cBioPortal49 448 
http://www.cbioportal.org/index.do, selecting Bladder Urothelial Carcinoma set (TCGA, 449 
provisional for 413 samples) or Breast Invasive Carcinoma set (TCGA, provisional for 1105 450 
samples) through Query mode. CNVs were downloaded by selecting Putative copy-number 451 
alterations from GISTIC53 in Select Genomic Profiles section. Germline genotypes are classified 452 
as controlled access data and they were acquired from TCGA upon approval by the data access 453 
committees of dbGAP and TCGA (https://tcga-data.nci.nih.gov/tcga/tcgaAccessTiers.jsp). 454 
Genotypes of germline variants were generated by TCGA with Affymetrix SNP 6 arrays for 455 
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DNA extracted from the blood of patients. TCGA samples are described in Table S17 and full 456 
dataset is provided as Supplementary Source File 1.  457 
Expression analysis in TCGA 458 
Analysis was performed with R package version 3.2.1 using multivariate linear regression 459 
models to calculate beta-coefficients, which represent the increase in the value of the dependent 460 
variable for every unit increase in the predictor variable, adjusting for effects of other variables. 461 
The RNA-seq mRNA expression levels for TCGA samples are presented as RNA-seq by 462 
expectation maximum (RSEM) values. These values were log10-transformed and quantile-463 
normalized according to a standard procedure of handling mRNA expression data50; the resulting 464 
values were normally distributed  based on a Shapiro-Wilks test. We analyzed expression of all 465 
individual transcripts for all genes in the region of interest because gene-level expression 466 
analysis may miss specific effects of isoforms. 467 
 468 
Specifically, analysis at the isoform level allowed us to assess the effects of the A3A deletion 469 
isoform (A3AB). We used linear regression for expression of A3A, A3B and A3AB with deletion 470 
genotypes (0, 1, or 2 deletion alleles), which were scored in a subset of TCGA samples in a 471 
previous report17 and observed strong correlations (Table S18) confirming that expression of 472 
A3AB isoform could be used as a proxy for germline A3AB deletion. We also confirmed that the 473 
distribution of the A3AB deletion genotypes in subsets of bladder and breast tumors in TCGA 474 
was similar to that of HapMap samples (Table S19).  475 
 476 
For the isoform-specific expression exploratory analysis, we first performed a regression analysis 477 
evaluating effects of rs17000526 genotype (coded as 0, 1, and 2 risk alleles), age, gender 478 
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(excluded from the breast cancer analysis as 99% of the participants were female), and race 479 
(Caucasian, African American, or Asian) on expression levels (Tables S4 and S5). For more 480 
detailed analyses of those isoforms that were significantly correlated with rs17000526 genotypes 481 
in the initial analysis, we incorporated additional information that can be relevant for mRNA 482 
expression. Somatic changes in tumor tissue might have resulted in aberrant DNA methylation or 483 
CNV51, thus we additionally adjusted for the effects of these factors on expression levels. DNA 484 
methylation levels for CpG sites upstream of A3B were quantile-normalized and tested for 485 
correlation with A3B expression. The CpG site with the strongest effect on expression, as 486 
measured by the beta-coefficients and p-values, was used for adjustment in subsequent analyses 487 
(Table S6).  488 
Analysis of APOBEC mutagenesis  489 
APOBEC-signature mutation data for TCGA samples were acquired from the Broad Institute 490 
Genome Data Analysis Center (GDAC)52 Firehose portal (April 15, 2015, stamp 491 
analyses_2015_04_02) through Firebrowse https://gdac.broadinstitute.org/ using “firehose_get” 492 
option. Specific updated details of datasets, analyses and data sources (doi:10.7908/C1NP23KG 493 
and doi:10.7908/C1ZS2VN9) are available at 494 
http://gdac.broadinstitute.org/runs/analyses__latest/reports/cancer/BLCA/Mutation_APOBEC/no495 
zzle.html; http://gdac.broadinstitute.org/runs/analyses__latest/reports/cancer/BRCA-496 
TP/Mutation_APOBEC/nozzle.html. For the APOBEC signature mutation analyses we used a 497 
file *_sorted_sum_all_fisher_Pcorr.txt” (provided in Supplementary Source File 1). In this file 498 
we used two variables: the “tCw_to_G+tCw_to_T” variable, which represents total counts of 499 
APOBEC-signature mutations and the “APOBEC_MutLoad_MinEstimate“variable, which 500 
accounts for statistical significance of enrichment and represents APOBEC-mutagenesis pattern 501 
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per sample. This variable is more stringent as many samples were not enriched at a statistically 502 
significant level and were classified as negative for APOBEC-signature mutations. Mutation 503 
counts were log10-transformed to improve normality of distribution. A p-value of 0.05 was used 504 
as a threshold for significance, unless specified otherwise and all tests were two-sided. The 505 
Bonferroni multiple comparisons significance level is reported where appropriate. We also 506 
downloaded from Firehose and analyzed an updated dataset for APOBEC mutagenesis (stamp 507 
analyses__2016_01_28); the results were very similar (data not shown) compared to those 508 
generated for the April 2015 dataset and reported here.   509 
Mutation analysis of selected genes in TCGA  510 
Data for functionally relevant somatic mutations53 in some frequently mutated genes and 511 
generated using MutSig2CV was downloaded from the Broad Institute Firebrowse 512 
http://firebrowse.org/#. The mutation data for each gene was obtained from “Aggregate Analysis 513 
Features” tab from file “_-TP.samplefeatures.txt” using column “SMG_mutsig.2CV_gene” 514 
(provided in Supplementary Source File 1). We evaluated distribution of mutations in bladder 515 
tumors in a panel of genes - TP53, RB1, ELF3, TSC1, PIK3CA, RHOB, CDKN2A, ARID1A, 516 
ZFP36L1, CDKN1A, ATM and FGFR3 and for TP53 in breast tumors in relation to rs17000526 517 
genotype groups. Statistical significance was evaluated based on 2x3 Chi-Square test, without 518 
adjustment for any other variables.   519 
Survival analysis  520 
Survival analysis was performed using TCGA data. Overall survival (OS) was defined as either 521 
months until patient death or last follow-up. The p-values and hazards ratios (HR) were derived 522 
from a multivariate Cox regression models that included age, gender (excluded in breast cancer 523 
analysis), tumor stage as core variables and additional variables such as SNP rs17000526, 524 
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APOBEC mutagenesis or mRNA expression of APOBEC3s. For APOBEC mutagenesis survival 525 
analysis was performed using mutation counts as continuous variable or in groups - quartiles or 526 
custom-defined. Treatment information (YES/NO any neoadjuvant or adjuvant treatment) was 527 
used in additional analyses. Univariate survival analysis in relation to APOBEC mutagenesis is 528 
also presented in Firehose doi:10.7908/C1G44PGV and later version doi:10.7908/C15T3JTD. 529 
http://gdac.broadinstitute.org/runs/analyses__2016_01_28/reports/cancer/BLCA-530 
TP/Correlate_Clinical_vs_Mutation_APOBEC_Continuous/V1-2.ex.pdf 531 
In silico functional annotation  532 
Annotation was performed using resources of ENCODE (available from UCSC genome 533 
Browser, https://genome.ucsc.edu/ENCODE/) and HaploReg.v4 534 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php). Analysis included data for 535 
chromatin immunoprecipitation and sequencing (ChIP-seq) for different histone marks, CTCF 536 
motifs, DNase hypersensitivity sites (DHS), formaldehyde-assisted isolation of regulatory 537 
elements (FAIRE-seq), and transcription factor binding sites (Txn Factor) from different cell 538 
lines. HaploReg analysis was performed using default settings for a European population and 539 
included annotation for enhancers, H3K4Me1 and H3K27Ac histone modification marks. 540 
Electrophoretic mobility shift assays (EMSA) 541 
Primers for the three SNPs were designed based on reference genomic sequences from dbSNP 542 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and purchased from Life Technologies: 543 
rs17000526_G-F: ATAAGGGCGTTGGGCAAGGAAA; rs17000526_G-R: 544 
TTTCCTTGCCCAACGCCCTTAT; rs17000526_A-F: ATAAGGGCGTTAGGCAAGGAAA; 545 
rs17000526_A-R: TTTCCTTGCCTAACGCCCTTAT; rs1014971_A-F: 546 
AGGTACTCCCAACCCCTGCAGC; rs1014971_A-R: GCTGCAGGGGTTGGGAGTACCT; 547 
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rs1014971_G-F: AGGTACTCCCGACCCCTGCAG C; rs1014971_G-R: 548 
GCTGCAGGGGTCGGGAGTACCT; rs1004748_G-F: GAAGCGGCAGGGCCAGCCATGTG; 549 
rs1004748_G-R: CACATGGCTGGCCCTGCCGCTTC; rs1004748_A-F: 550 
GAAGCGGCAGGACCAGCCATGTG; rs1004748_A-R: 551 
CACATGGCTGGTCCTGCCGCTTC.  552 
Primers were biotin-labelled using a 3’-end labelling kit (Pierce) and corresponding labelled 553 
forward and reverse primers were annealed to generate double-stranded allele-specific probes. 554 
Efficiency of biotin labelling was confirmed to be similar for each probe pair based on dot blot 555 
tests with serial dilutions. EMSA reactions were performed with a LightShift Chemiluminescent 556 
EMSA Kit (Thermo Scientific). Nuclear extracts were prepared from three bladder cancer cell 557 
lines (HT-1376, RT-4 and HTB-9) using a nuclear extraction kit (Active Motif) and commercial 558 
nuclear cell extracts were purchased from Active Motif for breast cancer cell lines (MCF-7, 559 
MDA-MB-231 and T-47D). Similar amounts of all nuclear extracts (10 μg) were used for 560 
reactions. For competition assays, unlabeled specific (self) and non-specific (opposite allele) 561 
probes were used at a 100-fold excess. Glycerol, NP-40, and MgCl2 were used to optimize the 562 
reactions. The reactions were incubated for 30 minutes at room temperature and protein 563 
complexes were immediately resolved on 6% DNA retardation gels (Invitrogen) for 1.5 h at 564 
100 V and transferred to Biodyne B Nylon Membranes (Pierce) for 40 min at 380 mA. 565 
Crosslinking was performed using Stratagene Stratalinker UV Crosslinker 2400 and membranes 566 
were probed using Chemiluminescent Nucleic Acid Detection Module (Pierce). 567 
Treatment with DNA-damaging drug and viral infection  568 
Bleomycin (sulfate) was purchased from Cayman Chemicals (Ann Arbor, Michigan). Bladder 569 
and breast cancer cells grown in 6-well plates were treated in triplicates or quadruplicates with 570 
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bleomycin (25 ug/ml) for 5 or 24 hours. Stocks of Sendai virus (SeV) strain Cantell were 571 
purchased from Charles River Laboratories (Wilmington, MA). SeV is a single-strand RNA 572 
murine parainfluenza virus which infects human cells and induces a robust antiviral interferon 573 
response that quickly controls infection30. Bladder and breast cancer cells were infected in 574 
triplicates or quadruplicates with SeV (7.5x105 CEID50/ml Chicken Embryo Infectious Dose 575 
50%) for 1 hour, washed with PBS and then collected at 0, 3, 6 and 12 hours post-infection.  576 
qRT-PCR analysis 577 
Total RNA for all experiments was isolated with an RNeasy kit with on-column DNase I 578 
treatment (Qiagen). RNA quantity and quality were evaluated by NanoDrop 8000 (Thermo 579 
Scientific). cDNA was prepared from equal amounts of total RNA per sample (10 ng per 5 ul 580 
reaction) with the RT2 first-strand cDNA kit and random hexamers with an additional DNA-581 
removal step (Qiagen). SeV loads were evaluated by qRT-PCR with virus-specific primers for 582 
SeV defective-interfering (SeV-DI) RNA: F: GTCAAGATGTTCGGGGCCAG and R: 583 
CGTTCTGCACGATAGGGACT. Expression of A3A, A3B, and A3G and endogenous controls 584 
GAPDH, ATCB, and PPIA was measured in the same cDNA with TaqMan expression assays – 585 
Hs00377444_m1 for A3A, Hs02564469_s1 for A3B, Hs01043989_m1 for A3G, and 4326317E 586 
for GAPDH, 4352935 for ATCB and 4326316E for PPIA (Life Technologies). Reactions were 587 
performed in four technical replicates on QuantStudio 7 (Life Technologies) using SYBR Green 588 
Rox qPCR Mastermix (Qiagen) or TaqMan Gene Expression buffer (Life Technologies); water 589 
and genomic DNA were used as negative controls for all assays. For antiviral pathway 590 
expression analysis, qRT-PCR mRNA expression analysis was performed using SYBR Green 591 
Antiviral Response qRT-PCR array (Qiagen). The plates included 88 expression assays for target 592 
genes, as well as positive, negative, and endogenous normalization controls (Table S10). 593 
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Reactions included 10 ng of total DNAse-treated RNA in 10 ul volume and were done for two 594 
biological replicates from each experimental condition. Expression was measured in Ct values 595 
(PCR cycle at detection threshold), which are distributed on log2 scale. Expression of 596 
APOBEC3s was normalized by the mean of endogenous controls (GAPDH, ACTB, and PPIA). 597 
Differences in expression were calculated according to the relative quantification method, as dCt 598 
= Ct (control)−Ct (target).  599 
 600 
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FIGURE LEGENDS 619 
 620 
Figure 1.  Fine-mapping analysis of the 22q13.1 region for association with bladder cancer 621 
risk. The plot is based on the combined NCI-GWAS1 and NCI-GWAS2 set, which includes 622 
2,301 imputed and 142 genotyped SNPs for 5,832 bladder cancer cases and 10,721 controls of 623 
European ancestry. The results are shown for a 400 Kb region centered on GWAS SNP 624 
rs1014971, the same region as was used for the eQTL analyses of TCGA data. Left y-axis 625 
represents the -log10 (P-values) for association with bladder cancer risk; right y-axis represents 626 
the recombination map of the region (cM/Mb), recombination hot spots are connected by line. 627 
The SNPs with the strongest signals are presented as colored diamonds; all other SNPs are 628 
presented as circles. The position of the deletion is marked by a grey rectangle; APOBEC3AB 629 
(A3AB) deletion isoform is labeled within gene track.  630 
 631 
Figure 2. Analysis of factors contributing to APOBEC mutagenesis in bladder and breast 632 
tumors in TCGA. (A-D). Quantile-normalized log10 values of A3B mRNA expression in 633 
relation to rs17000526 genotypes and corresponding beta-coefficients for each variable. 634 
Quartiles and the means are marked by box-plot overlays. (E -H). Log10 values of the 635 
APOBEC-signature mutations in relation to rs17000526 genotypes and corresponding beta-636 
coefficients for each variable. (J and L). Log10 values of the APOBEC mutagenesis pattern in 637 
relation to rs17000526 genotypes and corresponding beta-coefficients for each variable. (M and 638 
O). Beta-coefficients for variables contributing to APOBEC-signature mutations. (N and P). 639 
Beta-coefficients for variables contributing to APOBEC mutagenesis pattern. Isoforms are 640 
annotated as the major, minor, or deletion (A3AB) transcripts as presented in Table S4. Beta-641 
coefficients labeled in blue and red indicate positive and negative correlations, respectively. 642 
Male gender and European ancestry are used as reference groups. The CNV variable represents 643 
somatic copy number variation of A3B. P-values are based on multivariate linear regression 644 
analysis: *<0.05; **<0.005, ***<0.0005. Data used for this analysis is presented in 645 
Supplementary Source File 1. 646 
 647 
 648 
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Figure 3.  In silico and experimental analysis of the 2 Kb region that includes GWAS SNP 649 
rs1014971 and its two proxy SNPs (r2 ≥ 0.8, in Europeans). (A). In silico functional analysis 650 
based on ENCODE and HaploReg.v4 resources. The plot shows signals detected by chromatin 651 
immunoprecipitation and sequencing (ChIP-seq) for different histone marks, CTCF motifs 652 
(insulators), DNase hypersensitivity sites (DHS), formaldehyde-assisted isolation of regulatory 653 
elements (FAIRE-seq), transcription factor binding sites (Txn Factor), and enhancers from cell 654 
lines. Red bars represent signals which overlay the SNPs and green bars represent signals 655 
adjacent to SNPs. Numbers on red bars for HaploReg data mark numbers of tissues/cell lines 656 
positive for the indicated marks; underlined are weak signals. Enrichment of putative functional 657 
signals is observed around SNP rs17000526. (B). Experimental analysis with electrophoretic 658 
mobility shift assays (EMSA) for the three associated APOBEC3 SNPs. Red boxes mark allele-659 
specific differences for interaction of SNP rs1014971 with nuclear cell extracts from bladder and 660 
breast cancer cell lines. Competition assays were performed with 100-fold excess of unlabeled 661 
specific (self) and non-specific (opposite allele) probes. In both bladder cancer cell lines binding 662 
was observed only for the risk rs1014971-T allele, while in breast cancer cell line binding was 663 
also detected for the non-risk rs1014971-C allele, although it was weaker than for the risk 664 
rs1014971-T allele. For SNPs rs17000526 and rs1004748 no distinct allele-specific pattern of 665 
binding was observed.  666 
 667 
Figure 4. Expression of APOBEC3s in HT-1376 bladder and MCF-7 breast cancer cell lines 668 
infected with Sendai virus (SeV) or treated with DNA-damaging drug bleomycin (Bleo). (A 669 
and C). Increased viral load shows that cells were successfully infected with SeV based on qRT-670 
PCR for a viral-specific transcript; data is presented on log2 scale compared to non-infected 671 
samples. (B and D). Expression of A3A, A3B, and A3G in untreated HT-1376 and MCF-7 cells –672 
A3A is expressed significantly lower than A3B; A3G is not detectable in MCF-7 cells. (E and G). 673 
A3A, A3B and A3G are significantly induced by SeV infection in both cell lines. (F and H). 674 
mRNA expression analysis of A3A, A3B, and A3G in cells untreated (UT) or treated with 675 
bleomycin for 5 and 24 hours. Expression of A3B and A3G was significantly induced after 24 676 
hours of treatment in HT-1376 but not in MCF-7 cells. P-values are calculated between control 677 
and experiment groups using two-sided T-test. Shown are values for individual biological 678 
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replicates and means, normalized to endogenous controls and presented on log2 scale. Data used 679 
for this analysis is presented in Supplementary Source File 2. 680 
 681 
Figure 5. Overall survival of TCGA bladder cancer patients is improved with increased 682 
APOBEC mutagenesis and in carriers of bladder cancer risk genotype rs17000526-AA. (A 683 
and B). APOBEC-signature mutations and APOBEC mutagenesis pattern were divided into 684 
quartiles (I - lowest and IV - highest mutation loads) and plotted against months of overall 685 
survival (OS). Multivariate Cox regression models were used to calculate hazards ratios (HR) 686 
with 95% confidence intervals (CI) and p-values for quartiles II, III, or IV vs. I (reference) as 687 
well as III and IV vs I and II. (C). Hazards ratios for SNP rs17000526 were calculated by 688 
comparing the AA or AG vs. GG genotype (reference) or AA vs. AG and GG genotypes 689 
(reference). Multivariate models included age, gender, and tumor stage variables. Data used for 690 
this analysis is presented in Supplementary Source File 1. 691 
 692 
Figure 6.  Schematic representation of factors contributing to APOBEC mutagenesis and 693 
its role in cancer.  (A). Cis-factors in the 22q13.1 region affecting A3A and A3B expression. 694 
Germline variants: SNP rs1014971, which is located within a putative long-range enhancer of 695 
A3B, and a 30 Kb germline deletion A3AB, which eliminates A3B and creates chimeric and more 696 
stable A3AB transcript that generates A3A enzyme. Expression of these transcripts can be 697 
modified by binding of transcription factors to A3B enhancer, DNA methylation (marked as M) 698 
at a CpG site cg21707131 within the A3B promoter, and somatic copy number variation (CNV) 699 
of the A3B region (B). Genetic, molecular and clinical associations. Expression of A3A, A3AB 700 
and A3B transcripts can be induced by environmental factors such as DNA-damaging agents and 701 
viral infections that activate interferon-stimulated innate immune response. A3A and A3B 702 
enzymes generated by these transcripts can contribute to mutagenesis in the right cellular 703 
environment that can be modified by additional factors affecting availability of single-stranded 704 
DNA (ssDNA) that is a necessary source for APOBEC mutagenesis, etc. SNP rs1014971 shows 705 
important associations predominantly for bladder cancer - with increased cancer risk, A3B 706 
expression, APOBEC mutagenesis and survival, while A3AB deletion shows associations with 707 
breast cancer. (C). Hypothesis for the combined role of germline and environmental factors 708 
in APOBEC mutagenesis. In normal tissues A3A/A3B levels increase with the number of risk 709 
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alleles of germline variants (SNP rs1014971 or A3AB deletion) but are still below the genotoxic 710 
threshold. Even transient exposures to DNA-damaging agents or viral infections can induce 711 
A3A/A3B levels above the genotoxic threshold, especially in individuals with risk germline 712 
variants who have higher levels already at baseline. Mutagenesis and tumor initiation can occur 713 
if ssDNA is available endogenously (DNA replication and repair) or generated by DNA-714 
damaging exposures. In the tumor microenvironment ssDNA can be available from DNA 715 
damage due to genomic instability and cancer therapies; continuous DNA damage maintains 716 
high A3B/A3A levels above genotoxic levels. Depending on cancer type and other contributing 717 
factors high APOBEC mutagenesis may be associated either with improved survival due to 718 
increased immune surveillance and synthetic lethality of tumor cells, or with decreased survival 719 
due to tumor evolution and progression.       720 
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TABLES 721 
 722 
Table 1. Association of A3AB deletion with bladder cancer risk in individuals of European ancestry, a Japanese population, and the 723 
combined set 724 
Deletion 
genotype     
European ancestry Japanese Meta-analysis Heteroge-
neity 1,719 cases and 2,566 controls 1,116 cases and 945 controls 2,835 cases and 3,511 controls  
Cases,      
N (%) 
Controls,    
N (%) 
OR 
(CI)* P-val* 
Cases,       
N (%) 
Controls,    
N (%) OR (CI) P-val OR (CI) P-val P-val 
I/I 1,531 (89.06) 
2,221       
(86.55) ref - 
622         
(55.73) 
495  
(52.38) ref - ref - - 
I/D or D/D 188         (10.94) 
345         
(13.45) 0.78 0.044 
494 
 (44.27) 
450 
 (47.62) 
0.87         
(0.73 - 1.04) 0.128 
0.85          
(0.74 - 0.97) 0.013 0.66 
A3AB deletion alleles: I - insertion, D –deletion; A3AB deletion genotypes: deletion absence (I/I) vs. deletion presence (I/D or D/D); 725 
*ORs and p-values are adjusted for age, sex, smoking status, and study site (SBCS, Spain and PLCO, USA). 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
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Table 2. Association of SNP rs1014971 and A3AB deletion haplotypes with bladder cancer risk in individuals of European ancestry, a 734 
Japanese population, and the combined set 735 
Haplotype 
SNP-
deletion 
Haplotype 
effect 
European ancestry Japanese Meta-analysis 
1,717 cases and 2,525 controls 1,097 cases and 898 controls 2,814 cases and 3,423 controls 
Cases, 
N (%) 
Controls, 
 N (%) OR (CI)* P-val* 
Cases, N 
(%) 
Controls,  
N (%) OR (CI) P-val OR (CI)* P-val 
1 T_I R_R 2,393 (69.69) 
3,261 
(64.49) ref - 954 (43.48) 707 (39.37) ref - ref - 
2 C_I P_R 843 (24.55) 
1,446 
(28.63) 
0.85 
(0.76-0.94) 0.001 674 (30.72) 595 (33.13) 
0.83 
(0.70-0.97) 0.023 
0.84 
(0.77-0.92) 3.6 x10
-5 
3 C_D P_P 147 (4.28) 275 (5.45) 
0.78 
(0.63-0.97) 0.024 544 (24.79) 477 (26.56) 
0.82 
(0.69-0.98) 0.033 
0.8 
(0.70-0.92) 0.002 
4 T_D R_P 51 (1.49) 68 (1.35) 
1.01 
(0.69-1.48) 0.963 
22 
(1.0) 
17 
(0.95) 
1.08 
(0.69-1.48) 0.835 
1.03 
(0.73-1.44) 0.89 
 
Haplotypes include SNP rs1014971 with alleles T and C and the A3AB deletion with alleles I – insertion and D - deletion; 736 
Haplotype effect: P - protective, R – risk, based on association with bladder cancer risk; *ORs and p-values are adjusted for age, sex, smoking, and 737 
study site (SBCS, Spain and PLCO, USA). N – number of chromosomes. The haplotype in which the risk effect of rs1014971-T allele could be 738 
neutralized by the deletion allele (haplotype 4) is uncommon in both populations (~1-1.5% in Europeans and Japanese). The haplotype with the 739 
protective rs1014971-C allele and the deletion allele (haplotype 3) is uncommon in Europeans (~5%) and common in the Japanese (~25%), but the 740 
protective effect of this haplotype is similar to that of the haplotype with the protective allele of rs1014971 alone (haplotype 2).741 
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